

CURRENT REPORT 47/2023

December 7, 2023

Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") announces that it will present translational data for RVU120 at the San Antonio Breast Cancer Symposium 2023, which takes place December 5-9, 2023, in San Antonio, Texas.

Translational studies showed single agent activity of RVU120 in breast cancer mammosphere models in different subtypes. Synergistic activity was observed in combination with MEK inhibitors, especially in models with demonstrated EGFR amplification and RAS pathway activation. These findings provide insight into the synergistic potential of the combination in hormone-negative breast cancers – a subtype particularly challenging to treat. Simultaneously, RVU120 is currently being evaluated in nonclinical studies in additional solid tumors.

The conductment of the following studies is in-line with RVU120 Development Plan update, presented on October 23, 2023 in the current report no. 45/2023.

Abstract Title: “Synergistic Activity of CDK8/19 Inhibitor RVU120 and MEK Inhibitors in Hormone-Negative Breast Cancer: Implications for Targeted Therapy”

Session Name: Poster Session 4

Session date and time: Thursday, December 7, 2023, 5:00 PM - 7:00 PM CT

Poster Number: PO4-14-01

In the study, the responsiveness of RVU120, a highly selective and potent CDK8/CDK19 inhibitor, was evaluated in combination with MEK inhibitors in hormone-negative breast cancer. The cell lines where the synergy between CDK8/CDK19 inhibitors and MEK inhibitors was observed exhibited EGFR amplification and markers of an activated RAS pathway. This pattern of response was consistent across different MEK and MEK/RAF inhibitors, including selumetinib, trametinib, and avutometinib. In addition, sustained activation of both AKT and mTORC1 signaling was identified as a candidate resistance marker predicting synergistic activity of a RVU120/MEKi combination. These findings highlight the synergistic potential of combining RVU120 with MEK inhibitors in hormone-negative BC, particularly in triple negative breast cancer (TNBC) with EGFR amplification and an active RAS pathway.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations

may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Hendrik Nogai – Member of the Management Board